Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05908448 · ClinicalTrials.gov registry record
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
A clinical trial, sponsored by Sinocare.
- Completed
- Registry status
- 134
- Enrollment target
NCT05908448: Completed study, sponsored by Sinocare.
NCT05908448 is a clinical trial that has completed, run by Sinocare. The registered enrollment target is 134 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05908448 has completed, sponsored by Sinocare.
- COMPLETED
- Registry status
- 134 participants
- Enrollment target
Study Summary
The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
Primary Outcome
percentage of iCGM values in the measuring range less than 70 mg/dL (3.9 mmol/l) within +/- 15 mg/dL (0.83 mmol/l) of the YSI control
Interventions
- DEVICE 13 CGM (continuous glucose monitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2024-11-13 |
What the finished NCT05908448 record still lists
NCT05908448 is an observational study that tracks outcomes without assigning an intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which 13 CGM (continuous glucose monitor) is the first listed.
NCT05908448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05908448 about?
NCT05908448 is a clinical study titled "The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus". The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
What is the current status of trial NCT05908448?
This trial is currently completed. The enrollment target is 134 participants. The study started on 2024-02-07. Estimated completion is 2024-11-13.
What interventions are being tested in trial NCT05908448?
The interventions under investigation include: 13 CGM (continuous glucose monitor) (DEVICE).
Who is sponsoring clinical trial NCT05908448?
This trial is sponsored by Sinocare, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI